ArticlePloS one2008
HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.
Anthony Kong et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
36 papers cite it
this papercites it